Literature DB >> 12379637

Integrin alpha V beta 3 as a target for treatment of rheumatoid arthritis and related rheumatic diseases.

R L Wilder1.   

Abstract

A substantial and persuasive body of data now exists that supports the view that integrin alpha V beta 3 plays a critical part in activated macrophage dependent inflammation, osteoclast development, migration, and bone resorption, and inflammatory angiogenesis. All of these processes play an important part in the pathogenesis of rheumatoid arthritis (RA) and related arthropathies. Animal arthritis model data further support these concepts and also suggest that therapeutic antagonism of integrin alpha V beta 3 is worthy of further investigation in RA and related arthropathies. To this end, Vitaxin, also known as MEDI-522, has been developed. Vitaxin is a humanised monoclonal IgG1 antibody that specifically binds a conformational epitope formed by both the integrin alpha V and beta 3 subunits. It blocks the interaction of alpha V beta 3 with various ligands such as osteopontin and vitronectin. Clinical trials with Vitaxin in patients with RA are in progress.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12379637      PMCID： PMC1766704          DOI： 10.1136/ard.61.suppl_2.ii96

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


  51 in total

Review 1.  Cellular mechanisms and the role of cytokines in bone erosions in rheumatoid arthritis.

Authors:  E M Gravallese; S R Goldring
Journal:  Arthritis Rheum       Date:  2000-10

2.  Integrin indecision.

Authors:  Peter Carmeliet
Journal:  Nat Med       Date:  2002-01       Impact factor: 53.440

3.  Stepwise in vitro affinity maturation of Vitaxin, an alphav beta3-specific humanized mAb.

Authors:  H Wu; G Beuerlein; Y Nie; H Smith; B A Lee; M Hensler; W D Huse; J D Watkins
Journal:  Proc Natl Acad Sci U S A       Date:  1998-05-26       Impact factor: 11.205

4.  Tumor necrosis factor alpha regulates alpha(v)beta5 integrin expression by osteoclast precursors in vitro and in vivo.

Authors:  M Inoue; F P Ross; J M Erdmann; Y Abu-Amer; S Wei; S L Teitelbaum
Journal:  Endocrinology       Date:  2000-01       Impact factor: 4.736

Review 5.  Bone resorption by osteoclasts.

Authors:  S L Teitelbaum
Journal:  Science       Date:  2000-09-01       Impact factor: 47.728

6.  Expression of alpha v and beta 3 integrin subunits in rat osteoclasts in situ.

Authors:  D M Shinar; A Schmidt; D Halperin; G A Rodan; M Weinreb
Journal:  J Bone Miner Res       Date:  1993-04       Impact factor: 6.741

7.  Requirement of vascular integrin alpha v beta 3 for angiogenesis.

Authors:  P C Brooks; R A Clark; D A Cheresh
Journal:  Science       Date:  1994-04-22       Impact factor: 47.728

8.  Role of alpha(v)beta(3) integrin in osteoclast migration and formation of the sealing zone.

Authors:  I Nakamura; M F Pilkington; P T Lakkakorpi; L Lipfert; S M Sims; S J Dixon; G A Rodan; L T Duong
Journal:  J Cell Sci       Date:  1999-11       Impact factor: 5.285

9.  Integrin subunit expression by human osteoblasts and osteoclasts in situ and in culture.

Authors:  J Clover; R A Dodds; M Gowen
Journal:  J Cell Sci       Date:  1992-09       Impact factor: 5.285

10.  A role for the alphavbeta3 integrin in the transmigration of monocytes.

Authors:  D Weerasinghe; K P McHugh; F P Ross; E J Brown; R H Gisler; B A Imhof
Journal:  J Cell Biol       Date:  1998-07-27       Impact factor: 10.539
View more
  58 in total

Review 1.  Gallium-labelled peptides for imaging of inflammation.

Authors:  Anne Roivainen; Sirpa Jalkanen; Cristina Nanni
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-02       Impact factor: 9.236

Review 2.  CD23/FcεRII: molecular multi-tasking.

Authors:  M Acharya; G Borland; A L Edkins; L M Maclellan; J Matheson; B W Ozanne; W Cushley
Journal:  Clin Exp Immunol       Date:  2010-10       Impact factor: 4.330

3.  Angiogenesis blockade as a new therapeutic approach to experimental colitis.

Authors:  Silvio Danese; Miquel Sans; David M Spencer; Ivy Beck; Fernando Doñate; Marian L Plunkett; Carol de la Motte; Raymond Redline; David E Shaw; Alan D Levine; Andrew P Mazar; Claudio Fiocchi
Journal:  Gut       Date:  2006-12-14       Impact factor: 23.059

Review 4.  Trojan horses and guided missiles: targeted therapies in the war on arthritis.

Authors:  Mathieu Ferrari; Shimobi C Onuoha; Costantino Pitzalis
Journal:  Nat Rev Rheumatol       Date:  2015-03-03       Impact factor: 20.543

5.  Integrin alpha(v)beta(3)-Targeted Cancer Therapy.

Authors:  Zhaofei Liu; Fan Wang; Xiaoyuan Chen
Journal:  Drug Dev Res       Date:  2008       Impact factor: 4.360

6.  Differential regulation of monocyte cytokine release by αV and β(2) integrins that bind CD23.

Authors:  Adrienne L Edkins; Gillian Borland; Mridu Acharya; Richard J Cogdell; Bradford W Ozanne; William Cushley
Journal:  Immunology       Date:  2012-06       Impact factor: 7.397

7.  Interleukin 32 (IL-32) contains a typical α-helix bundle structure that resembles focal adhesion targeting region of focal adhesion kinase-1.

Authors:  Bas Heinhuis; Marije I Koenders; Wim B van den Berg; Mihai G Netea; Charles A Dinarello; Leo A B Joosten
Journal:  J Biol Chem       Date:  2011-12-27       Impact factor: 5.157

8.  68Ga-DOTA-E[c(RGDfK)]2 PET Imaging of SHARPIN-Regulated Integrin Activity in Mice.

Authors:  Riikka Siitonen; Emilia Peuhu; Anu Autio; Heidi Liljenbäck; Elina Mattila; Olli Metsälä; Meeri Käkelä; Tiina Saanijoki; Ingrid Dijkgraaf; Sirpa Jalkanen; Johanna Ivaska; Anne Roivainen
Journal:  J Nucl Med       Date:  2019-03-08       Impact factor: 10.057

9.  The investigation of synovial genomic targets of bucillamine with microarray technique.

Authors:  Kenji Oki; Fumio Tsuji; Koji Ohashi; Masaaki Kageyama; Hiroyuki Aono; Minoru Sasano
Journal:  Inflamm Res       Date:  2009-03-17       Impact factor: 4.575

Review 10.  Non-oncological applications of RGD-based single-photon emission tomography and positron emission tomography agents.

Authors:  Thomas Ebenhan; Janke Kleynhans; Jan Rijn Zeevaart; Jae Min Jeong; Mike Sathekge
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-09-12       Impact factor: 9.236
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.